Drug Profile
HIV T-cell therapy - Benitec/City of Hope
Alternative Names: Lentivirus-transduced T-cell immunotherapy; pHIV7-shI-TAR-CCR5RZ treated CD4 cellsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator City of Hope National Medical Center
- Developer Benitec Biopharma; City of Hope National Medical Center
- Class Cell therapies; RNA; Small interfering RNA
- Mechanism of Action Immunostimulants; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-0 development in HIV-infections in USA (IV, Infusion)
- 09 Feb 2011 Development is ongoing in USA
- 13 Nov 2009 Preclinical development is ongoing